Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., . . . Kagamu, H. (2019). Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Wiley.
Chicago-tyylinen lähdeviittausYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
MLA-viiteYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.